Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy.

Xiong Z, Ampudia Mesias E, Pluhar GE, Rathe SK, Largaespada DA, Sham YY, Moertel CL, Olin MR.

Clin Cancer Res. 2020 Jan 1;26(1):232-241. doi: 10.1158/1078-0432.CCR-19-2234. Epub 2019 Oct 17.

2.

Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma.

Olin MR, Ampudia-Mesias E, Pennell CA, Sarver A, Chen CC, Moertel CL, Hunt MA, Pluhar GE.

Cancers (Basel). 2019 Jan 24;11(2). pii: E137. doi: 10.3390/cancers11020137.

3.

Tumor-derived exosomes, microRNAs, and cancer immune suppression.

Graner MW, Schnell S, Olin MR.

Semin Immunopathol. 2018 Sep;40(5):505-515. doi: 10.1007/s00281-018-0689-6. Epub 2018 Jun 4. Review.

4.

Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.

Xiong Z, Ampudia-Mesias E, Shaver R, Horbinski CM, Moertel CL, Olin MR.

Immunotherapy. 2016 Sep;8(9):1059-71. doi: 10.2217/imt-2016-0033.

5.

Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant.

Andersen BM, Xia J, Epstein AL, Ohlfest JR, Chen W, Blazar BR, Pennell CA, Olin MR.

J Immunother Cancer. 2016 Feb 16;4:11. doi: 10.1186/s40425-016-0112-6. eCollection 2016.

6.

CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Pluhar GE, Pennell CA, Olin MR.

Crit Rev Immunol. 2015;35(2):153-72. Review.

7.

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.

Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR.

J Immunother Cancer. 2014 Dec 16;2(1):46. doi: 10.1186/s40425-014-0046-9. eCollection 2014.

8.

Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.

Olin MR, Pluhar GE, Andersen BM, Shaver R, Waldron NN, Moertel CL.

Crit Rev Immunol. 2014;34(5):399-432. Review.

9.

Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response.

Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, Nascene D, Gustafson MP, Dietz AB, Clark HB, Chen W, Blazar B, Ohlfest JR, Moertel C.

J Immunother Cancer. 2014 Feb 18;2:4. doi: 10.1186/2051-1426-2-4. eCollection 2014.

10.

Identification and characterization of a novel scFv recognizing human and mouse CD133.

Swaminathan SK, Niu L, Waldron N, Kalscheuer S, Zellmer DM, Olin MR, Ohlfest JR, Vallera DA, Panyam J.

Drug Deliv Transl Res. 2013 Apr;3(2):143-51. doi: 10.1007/s13346-012-0099-6.

11.

Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity.

Andersen BM, Pluhar GE, Seiler CE, Goulart MR, SantaCruz KS, Schutten MM, Meints JP, O'Sullivan MG, Bentley RT, Packer RA, Thomovsky SA, Chen AV, Faissler D, Chen W, Hunt MA, Olin MR, Ohlfest JR.

Cancer Res. 2013 May 15;73(10):2987-97. doi: 10.1158/0008-5472.CAN-12-3366. Epub 2013 Mar 7.

12.

Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model.

Ohlfest JR, Andersen BM, Litterman AJ, Xia J, Pennell CA, Swier LE, Salazar AM, Olin MR.

J Immunol. 2013 Jan 15;190(2):613-20. doi: 10.4049/jimmunol.1201557. Epub 2012 Dec 17.

13.

An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas.

Murphy KA, Lechner MG, Popescu FE, Bedi J, Decker SA, Hu P, Erickson JR, O'Sullivan MG, Swier L, Salazar AM, Olin MR, Epstein AL, Ohlfest JR.

Clin Cancer Res. 2012 Sep 1;18(17):4657-68. doi: 10.1158/1078-0432.CCR-12-0990. Epub 2012 Jul 10.

14.

9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma.

Teitelbaum AM, Gallardo JL, Bedi J, Giri R, Benoit AR, Olin MR, Morizio KM, Ohlfest JR, Remmel RP, Ferguson DM.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1519-27. doi: 10.1007/s00280-012-1855-5. Epub 2012 Mar 9.

PMID:
22402637
15.

Oxygen is a master regulator of the immunogenicity of primary human glioma cells.

Olin MR, Andersen BM, Litterman AJ, Grogan PT, Sarver AL, Robertson PT, Liang X, Chen W, Parney IF, Hunt MA, Blazar BR, Ohlfest JR.

Cancer Res. 2011 Nov 1;71(21):6583-9. doi: 10.1158/0008-5472.CAN-11-1166. Epub 2011 Sep 9.

16.

Superior efficacy of tumor cell vaccines grown in physiologic oxygen.

Olin MR, Andersen BM, Zellmer DM, Grogan PT, Popescu FE, Xiong Z, Forster CL, Seiler C, SantaCruz KS, Chen W, Blazar BR, Ohlfest JR.

Clin Cancer Res. 2010 Oct 1;16(19):4800-8. doi: 10.1158/1078-0432.CCR-10-1572. Epub 2010 Sep 21.

17.

Identification of a novel monoclonal antibody recognizing CD133.

Swaminathan SK, Olin MR, Forster CL, Cruz KS, Panyam J, Ohlfest JR.

J Immunol Methods. 2010 Sep 30;361(1-2):110-5. doi: 10.1016/j.jim.2010.07.007. Epub 2010 Jul 30.

PMID:
20674577
18.

In vivo morphine treatment synergistically increases LPS-induced caspase activity in immune organs.

Olin MR, Roy S, Molitor T.

J Neuroimmune Pharmacol. 2010 Dec;5(4):546-52. doi: 10.1007/s11481-010-9209-8.

19.

Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy.

Pluhar GE, Grogan PT, Seiler C, Goulart M, Santacruz KS, Carlson C, Chen W, Olin MR, Lowenstein PR, Castro MG, Haines SJ, Ohlfest JR.

Vaccine. 2010 Apr 26;28(19):3371-8. doi: 10.1016/j.vaccine.2010.02.082. Epub 2010 Mar 1.

20.

Role of nitric oxide in defense of the central nervous system against Mycobacterium tuberculosis.

Olin MR, Armién AG, Cheeran MC, Rock RB, Molitor TW, Peterson PK.

J Infect Dis. 2008 Sep 15;198(6):886-9. doi: 10.1086/591097.

PMID:
18627273
21.

In vitro and in vivo apoptosis detection using membrane permeant fluorescent-labeled inhibitors of caspases.

Lee BW, Olin MR, Johnson GL, Griffin RJ.

Methods Mol Biol. 2008;414:109-35. Review.

PMID:
18175816
22.

Morphine modulates gammadelta lymphocytes cytolytic activity following BCG vaccination.

Olin MR, Choi K, Lee J, Peterson PK, Molitor TW.

Brain Behav Immun. 2007 Feb;21(2):195-201. Epub 2006 Jul 25.

PMID:
16870392
23.

Gammadelta lymphocyte response to porcine reproductive and respiratory syndrome virus.

Olin MR, Batista L, Xiao Z, Dee SA, Murtaugh MP, Pijoan CC, Molitor TW.

Viral Immunol. 2005;18(3):490-9.

PMID:
16212527
24.

Gammadelta T-lymphocyte cytotoxic activity against Mycobacterium bovis analyzed by flow cytometry.

Olin MR, Hwa Choi K, Lee J, Molitor TW.

J Immunol Methods. 2005 Feb;297(1-2):1-11. Epub 2004 Nov 12.

PMID:
15777926
25.

Gammadelta T cells in immunity induced by Mycobacterium bovis bacillus Calmette-Guérin vaccination.

Lee J, Choi K, Olin MR, Cho SN, Molitor TW.

Infect Immun. 2004 Mar;72(3):1504-11.

26.

The effect of collection site on the cytogram of the BASO/lobularity channel of a hematology system in the mouse.

Olin MR, Diters RW, Freden GO.

Vet Clin Pathol. 1997;26(2):63-65. No abstract available.

PMID:
12658596

Supplemental Content

Support Center